Market Cap (In GBp)
857.09 Million
Revenue (In GBp)
1.09 Billion
Net Income (In GBp)
2 Million
Avg. Volume
348.88 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 554.5-1770.0
- PE
- 343.5
- EPS
- 0.02
- Beta Value
- 0.272
- ISIN
- GB00BN4HT335
- CUSIP
- G4766E108
- CIK
- -
- Shares
- 124759000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Mark Crossley
- Employee Count
- -
- Website
- https://www.indivior.com
- Ipo Date
- 2014-12-22
- Details
- Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
More Stocks
-
IOMiomart Group plc
IOM
-
MONTFMontfort Capital Corp.
MONTF
-
BLSP
-
MLSML System S.A.
MLS
-
PMJS
-
NEOLANeola Medical AB (publ)
NEOLA
-
NOHONoHo Partners Oyj
NOHO
-
2970